Literature DB >> 11122894

Angiogenic molecules and mechanisms in breast cancer.

I Wu1, M A Moses.   

Abstract

One of the most promising and exciting anti-cancer strategies is one that is based on the inhibition of angiogenesis. Unlike conventional therapeutic approaches, anti-angiogenic therapy holds the unique promise of treating the disease in the absence of cytotoxicity or drug resistance. The link between angiogenesis and the progression of human breast cancer has been known for over 25 years, yet it is only in recent years, as endogenous stimulators and inhibitors of angiogenesis have been discovered and studied, that the promise of this therapeutic approach for breast cancer has come to be appreciated. This article presents a concise review of recent studies focused on the molecules and mechanisms that are related to the role of angiogenesis in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11122894     DOI: 10.1007/s11912-000-0111-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  43 in total

1.  Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.

Authors:  M Relf; S LeJeune; P A Scott; S Fox; K Smith; R Leek; A Moghaddam; R Whitehouse; R Bicknell; A L Harris
Journal:  Cancer Res       Date:  1997-03-01       Impact factor: 12.701

Review 2.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

Review 3.  The regulation of neovascularization of matrix metalloproteinases and their inhibitors.

Authors:  M A Moses
Journal:  Stem Cells       Date:  1997       Impact factor: 6.277

4.  Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.

Authors:  D W Dawson; O V Volpert; P Gillis; S E Crawford; H Xu; W Benedict; N P Bouck
Journal:  Science       Date:  1999-07-09       Impact factor: 47.728

5.  Induction of angiogenesis during the transition from hyperplasia to neoplasia.

Authors:  J Folkman; K Watson; D Ingber; D Hanahan
Journal:  Nature       Date:  1989-05-04       Impact factor: 49.962

6.  VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer.

Authors:  R Valtola; P Salven; P Heikkilä; J Taipale; H Joensuu; M Rehn; T Pihlajaniemi; H Weich; R deWaal; K Alitalo
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

7.  Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer.

Authors:  A Kranz; T Mattfeldt; J Waltenberger
Journal:  Int J Cancer       Date:  1999-06-21       Impact factor: 7.396

8.  Antiangiogenic activity of the cleaved conformation of the serpin antithrombin.

Authors:  M S O'Reilly; S Pirie-Shepherd; W S Lane; J Folkman
Journal:  Science       Date:  1999-09-17       Impact factor: 47.728

9.  Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells.

Authors:  T Fotsis; S Breit; W Lutz; J Rössler; E Hatzi; M Schwab; L Schweigerer
Journal:  Eur J Biochem       Date:  1999-08

10.  Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers.

Authors:  M Nguyen; H Watanabe; A E Budson; J P Richie; D F Hayes; J Folkman
Journal:  J Natl Cancer Inst       Date:  1994-03-02       Impact factor: 13.506

View more
  2 in total

Review 1.  A role for antiangiogenic therapy in breast cancer.

Authors:  Marsha A Moses; Jay Harper; Cecilia A Fernández
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

2.  MR molecular imaging of angiogenesis using targeted perfluorocarbon nanoparticles.

Authors:  S D Caruthers; P M Winter; S A Wickline; G M Lanza; J Keupp
Journal:  Medicamundi       Date:  2010
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.